• Pasithea reported positive interim Phase 1 data for PAS-004 in advanced solid tumors with MAPK-pathway mutations, including patients pretreated with BRAF or MEK inhibitors.
• The readout showed durable disease control in some heavily pretreated patients, with long-term dosing generally manageable and no major safety red flags reported.
• The trial protocol was expanded to push dose escalation higher using a tablet formulation, aiming to better define the drug’s profile for chronic use.
• An optional pilot food-effect substudy was added to guide dosing strategy.
• A fuller dataset is planned for presentation at a future scientific conference; the interim results have already been disclosed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pasithea Therapeutics Corporation published the original content used to generate this news brief on June 30, 2026, and is solely responsible for the information contained therein.